Prete, Alessandra Anna
Angerilli, Valentina
Bergamo, Francesca http://orcid.org/0000-0002-8795-4653
Vettore, Valentina
De Toni, Chiara
Intini, Rossana
Cerma, Krisida
Ricagno, Gianmarco
Cerantola, Riccardo
Perissinotto, Eleonora
De Rosa, Antonio
Ceccon, Carlotta
Gasparello, Jessica
Denaro, Luca
D’Amico, Alberto
Chioffi, Franco
Carcea, Elena
Fassan, Matteo http://orcid.org/0000-0001-6515-5482
Lonardi, Sara http://orcid.org/0000-0002-7593-8138
Article History
Received: 2 August 2023
Revised: 13 December 2023
Accepted: 21 December 2023
First Online: 12 February 2024
Competing interests
: FB (Francesca Bergamo) reports: advisory/consulting role for Servier and Novartis; speakers’ fee from Eli-Lilly, MSD, EISAI, Bayer, BMS. SL reports: research funding (to Institution) from Amgen, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daichii Sankyo, Hutchinson, Incyte, Merck Serono, Mirati, MSD, Pfizer, Roche, Servier; personal honoraria as invited speaker from Amgen, Bristol-Myers Squibb, Incyte, GSK, Lilly, Merck Serono, MSD, Pierre-Fabre, Roche, Servier; participation in advisory board for Amgen, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, GSK, Incyte, Lilly, Merck Serono, MSD, Servier, Takeda. MF (Matteo Fassan) reported personal fees (as speaker bureau or advisor) from Roche, MSD, GSK, Amgen, Lilly, Novartis, Astellas Pharma, Pierre Fabre, Astra Zeneca and received research grants from Astellas Pharma, QED Therapeutics, Diaceutics, and Macrophage Pharma. All of the above-mentioned financial relationships were outside this work. All remaining authors have declared no conflicts of interest.
: This research received approval from the local Ethics Committee. Written informed consent and consent for publication were obtained from each patient to participate in the study.